JANX vs. DICE, PAND, SRRK, PRAX, IGMS, ROIV, INSM, LEGN, ASND, and CERE
Should you be buying Janux Therapeutics stock or one of its competitors? The main competitors of Janux Therapeutics include DICE Therapeutics (DICE), Pandion Therapeutics (PAND), Scholar Rock (SRRK), Praxis Precision Medicines (PRAX), IGM Biosciences (IGMS), Roivant Sciences (ROIV), Insmed (INSM), Legend Biotech (LEGN), Ascendis Pharma A/S (ASND), and Cerevel Therapeutics (CERE). These companies are all part of the "medical" sector.
DICE Therapeutics (NASDAQ:DICE) and Janux Therapeutics (NASDAQ:JANX) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, community ranking, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.
Janux Therapeutics has higher revenue and earnings than DICE Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than DICE Therapeutics, indicating that it is currently the more affordable of the two stocks.
Janux Therapeutics received 7 more outperform votes than DICE Therapeutics when rated by MarketBeat users. Likewise, 60.53% of users gave Janux Therapeutics an outperform vote while only 40.00% of users gave DICE Therapeutics an outperform vote.
In the previous week, Janux Therapeutics had 14 more articles in the media than DICE Therapeutics. MarketBeat recorded 14 mentions for Janux Therapeutics and 0 mentions for DICE Therapeutics. DICE Therapeutics' average media sentiment score of 0.28 beat Janux Therapeutics' score of 0.00 indicating that Janux Therapeutics is being referred to more favorably in the news media.
75.4% of Janux Therapeutics shares are owned by institutional investors. 4.9% of DICE Therapeutics shares are owned by company insiders. Comparatively, 35.4% of Janux Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
DICE Therapeutics has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500. Comparatively, Janux Therapeutics has a beta of 3.71, meaning that its stock price is 271% more volatile than the S&P 500.
DICE Therapeutics has a net margin of 0.00% compared to DICE Therapeutics' net margin of -762.92%. DICE Therapeutics' return on equity of -13.49% beat Janux Therapeutics' return on equity.
DICE Therapeutics presently has a consensus price target of $48.00, suggesting a potential upside of 0.95%. Janux Therapeutics has a consensus price target of $66.29, suggesting a potential upside of 50.10%. Given DICE Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Janux Therapeutics is more favorable than DICE Therapeutics.
Summary
Janux Therapeutics beats DICE Therapeutics on 15 of the 18 factors compared between the two stocks.
Get Janux Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for JANX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding JANX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Janux Therapeutics Competitors List
Related Companies and Tools
